血管生成
癌症研究
PTEN公司
星形细胞瘤
血管内皮生长因子
生物
p14arf公司
PDGFB公司
缺氧诱导因子
缺氧(环境)
下调和上调
血栓反应蛋白1
病理
生长因子
胶质瘤
抑癌基因
医学
基因
血小板源性生长因子受体
信号转导
细胞生物学
化学
癌变
受体
PI3K/AKT/mTOR通路
遗传学
血管内皮生长因子受体
有机化学
氧气
摘要
Angiogenesis is required for the development and biologic progression of infiltrative astrocytomas and takes the form of "microvascular hyperplasia" in glioblastoma multiforme, the most malignant astrocytoma. This pathologic term refers to an abnormal vascular proliferation that is often associated with necrosis and likely originates in hypoxic zones. Both the physiologic response to hypoxia and genetic alterations contribute to this process. The presence of hypoxic regions within an expanding tumor mass leads to upregulation of pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), through increased activity of the transcriptional complex HIF-1 (hypoxia-inducible factor-1). HIF-1 mediated gene expression may be directly or indirectly modulated by alterations in oncogenes/tumor suppressor genes that occur during astrocytoma development, including PTEN, TP53, p16(CDKN2A), p14ARF, EGFR, and PDGFR. Genetic alterations are also believed to influence the HIF-independent expression of pro- and anti- angiogenic factors, such as basic fibroblast growth factor (bFGF) and thrombospondin-1 (TSP-1), respectively. Thus, genetic events that occur during the progression of infiltrating astrocytomas promote angiogenesis, both by modulating hypoxia induced gene expression and by regulating of pro- and anti- angiogenic factors.
科研通智能强力驱动
Strongly Powered by AbleSci AI